Analysis of Smear Microscopy and Culture Conversion Results in Multidrug-Resistant Tuberculosis Patients with and without Type 2 Diabetes Mellitus

Henny Fauziah, Aprianti S., Handayani I., Kadir NA

Abstract


 

 

The World Health Organization (WHO) recommended microscopic AFB smear examination and culture as follow-ups to the response of MDR TB therapy. Analyzed the results of microscopic AFB smear and culture conversion as well as treatment outcome in Multidrug-Resistant Tuberculosis (MDR-TB) patients with and without Diabetes Mellitus (DM). This is a retrospective study involved 70 MDR-TB patients with (27 patients) with DM and without DM (43 patients) who had microscopic AFB smear and culture results at the start of the follow-up therapy. This research was conducted at Labuang Baji Regional Public Hospital, Makassar, from June to July 2019, used medical records of MDR-TB patients the period of June 2016 to December 2017. The results showed that 52 out of 70 MDR-TB patients had microscopic AFB smear and culture conversion in MDR-TB with DM (21 patients) and without DM (31 patients). The duration of microscopic AFB smear conversion in MDR TB patients with DM (3.33±0.54 months) was longer than patients without DM (2.07±0.05 months), p=0.001. While in culture conversion, there was no significant difference between MDR-TB with DM (1.28±0.64 months) and without DM (1.25±0.59), p=0.648. The recovery outcome between MDR-TB with (48.1%) and without DM (48.8%) was not significantly different. However, the output of treatment failure was greater in DM (11.2%) than without DM (2.3%), although statistically, there was no significant difference (p=0.568). Multidrug-resistant tuberculosis patients with DM experienced slower microscopic AFB smear conversion than MDR-TB patients without DM. However, in culture, there was no significant difference in the conversion period between the two groups. MDR-TB patients, both of with and without DM, had the same chance of recovery.


Keywords


Multidrug-resistant tuberculosis, with diabetes mellitus, without diabetes mellitus, microscopic AFB smear, culture

Full Text:

PDF

References


Kementrian kesehatan RI. Petunjuk Teknis Manajemen Terpadu Pengendalian Tuberkulosis Resistan Obat. Direktorat pengendalian penyakit dan penyehatan lingkungan. 2014

World Health Organization. What is multidrug-resistant tuberculosis (MDR-TB) and how do we control it.2018

Fachri M, Hatta M, Abadi S, Santoso SS, Wikanningtyas TA, Syarifuddin A, Dwiyanti R, Noviyanthi RA. Comparison of acid fast bacilli (AFB) smear for Mycobacterium tuberculosis on adult pulmonary tuberculosis (TB) patients with type 2 diabetes mellitus (DM) and without type 2 DM. Respiratory medicine case reports. 2018 Jan 1;23:158-62.

Dousa KM, Hamad A, Alsoub H, et al. Impact of Diabetes Mellitus on the Presentation and Response to Treatment of Adults With Pulmonary Tuberculosis in Qatar. InOpen Forum Infectious Diseases .2018 Nov (Vol. 5, No. Suppl 1, p. S274). Oxford University Press.

Badawi A, Sayegh S, Sallam M, Sadoun E, Al-Thani M, Alam MW, Arora P. The global relationship between the prevalence of diabetes mellitus and incidence of tuberculosis: 2000-2012. Global journal of health science. 2015 Mar;7(2):183

Rasool G, Khan AM, Mohy-Ud-Din R, Riaz M. Detection of Mycobacterium tuberculosis in AFB smear-negative sputum specimens through MTB culture and GeneXpert® MTB/RIF assay. International journal of immunopathology and pharmacology. 2019 Feb;33:2058738419827174.

Alene KA, Viney K, Yi H, McBryde ES, Yang K, Bai L, Gray DJ, Xu Z, Clements AC. Comparison of the validity of smear and culture conversion as a prognostic marker of treatment outcome in patients with multidrug-resistant tuberculosis. PloS one. 2018 May 23;13(5):e0197880

Shibabaw A, Gelaw B, Wang SH, Tessema B. Time to sputum smear and culture conversions in multidrug resistant tuberculosis at University of Gondar Hospital, Northwest Ethiopia. PloS one. 2018 Jun 26;13(6):e0198080.

Nurbiah N. Gambaran Faktor Risiko Pengobatan Pasien Multidrug Resistance Tuberculosis (MDR-TB) di RSUD Labuang Baji Kota Makassar Tahun 2017 (Doctoral dissertation, Universitas Islam Negeri Alauddin Maksassar).

Yanti, Zeni. Pengaruh Diabetes Melitus Terhadap Keberhasilan Pengobatan TB Paru Di Puskesmas Tanah Kalikedinding. Jurnal Berkala Epidemiologi, 2017, 5: 163-173.

Munoz-Torico, Marcela, et al. Comparison of bacteriological conversion and treatment outcomes among MDR-TB patients with and without diabetes in Mexico: Preliminary data. Revista Portuguesa de Pneumologia (English Edition), 2017, 23.1: 27-30.

Mahishale, Vinay, et al. Effect of poor glycemic control in newly diagnosed patients with smear-positive pulmonary tuberculosis and type-2 diabetes mellitus. Iranian journal of medical sciences, 2017, 42.2: 144

Baker, Meghan A., et al. The impact of diabetes on tuberculosis treatment outcomes: a systematic review. BMC medicine, 2011, 9.1: 81

Mihardja, Laurentia; Lolong, et al. Prevalensi Diabetes Melitus pada Tuberkulosis dan Masalah Terapi. Jurnal Ekologi Kesehatan, 2015, 14.4: 350-358.

Magee, Matthew J., et al. Diabetes mellitus, smoking status, and rate of sputum culture conversion in patients with multidrug-resistant tuberculosis: a cohort study from the country of Georgia. PLoS One, 2014, 9.4: e94890.

Departemen Kesehatan RI. Modul Kultur dan Uji kepekaan M.Tuberculosis terhadap obat anti tuberculosis lini pertama.2008

Cornelius. Angka Konversi Sputum Basil Tahan Asam pada Pasien Tuberkulosis Paru dengan Diabetes Melitus di Unit Pengobatan Penyakit Paru-paru Provinsi Kalimantan Barat Tahun 2009-2013. Jurnal Mahasiswa PSPD FK Universitas Tanjungpura.

Viswathan, Vijay, et al. Effect of diabetes on treatment outcome of smear-positive pulmonary tuberculosis—a report from South India. Journal of Diabetes and its Complications, 2014, 28.2: 162-165.

Sarin, R., et al. Smear microscopy as surrogate for culture during follow up of pulmonary MDR TB patients on DOTS plus treatment. Indian J Tuberc, 2010, 57.3: 134-140.




DOI: http://dx.doi.org/10.24293/ijcpml.v26i3.1590

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.